Investago | logo
Investago
Investago
Investago | Acadia and Neuren Ink Global Licensing Deal
Time to read: 1 minutes
Acadia and Neuren Ink Global Licensing Deal

Shares in Acadia Pharmaceuticals surged by almost 25% in the latest trading session, finishing at $32.18.*

acadia1

Performance of ACADIA Pharmaceuticals Inc over 5 years. Source: investing.com

This big jump is thanks to an exciting announcement about a deal with Neuren Pharmaceuticals. As part of the deal, Acadia will now be able to sell the drug trofinetide outside of North America. Plus, Acadia has bagged exclusive rights to a drug in development by Neuren, known as NNZ-2591, for the treatment of Rett syndrome and Fragile X syndrome. In return, Neuren will get a $100 million payment upfront, along with the possibility of further payments based on future success. Even though Acadia is expected to report a slight loss of $0.22 per share in its upcoming report, experts are feeling optimistic. They've increased their earnings estimate for the company by 7.7% over the last month, hinting at a possible increase in the share price in the future. On the other hand, Tango Therapeutics, another company in the same industry, saw a slight dip in its share price. It closed at $3.43, which is a 0.6% decrease.*

acadia2

Performance of Tango Therapeutics Inc over 5 years. Source: investing.com

The company's earnings estimate for the upcoming report hasn't changed over the past month and remains at a loss of $0.35 per share.

 

* Past performance is no guarantee of future results

 

Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 88.24% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Investago
Test your knowledge
Are you curious about your trading level? Now it's time for you to take this trading quiz questions. In the quiz you will find a few questions which are designed that you will have a better understanding of trading after. We wish you best luck!
Related news
Investago
18. August 2024
Lam Research: A Strategic Buy Amid Market Volatility

Lam Research (LRCX), a key player in the semiconductor manufacturing equipment industry, has seen its stock decline nearly 30% during the recent tech sell-off.* Despite this drop, the company remains a st...

Read more
Investago
30. July 2024
Evaluating JPMorgan’s Investment Potential

JPMorgan Chase (NYSE: JPM) has delivered a remarkable total return of 365% over the past decade, outperforming the S&P 500. As of July 25, its market cap reached $599 billion. The bank posted strong Q...

Read more
Investago
19. June 2024
Disney's Growth Potential - Buy Now?

The Walt Disney Company (NYSE: DIS) has encountered a challenging three years, with rising costs, waning interest in theatrical films, the ongoing decline of cable TV, and an activist investor's influence...

Read more
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 88.24% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.